NICE backs EUSA’s RCC treatment Fotivda
EUSA Pharma has gained backing from NICE for its first-line treatment for advanced renal cell carcimona (RCC), Fotivda. The recommendation from the UK’s regulatory body was decided on the result of the phase III trial TiVO-1, which evaluated the efficacy and tolerability of Fotivda compared to Bayer’s Nexavar.